Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3NY
|
|||
| Former ID |
DNC008330
|
|||
| Drug Name |
AM-1241
|
|||
| Synonyms |
444912-48-5; AM1241; AM-1241; (2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone; ZUHIXXCLLBMBDW-UHFFFAOYSA-N; AM 1241; GTPL3316; SCHEMBL2030690; CHEMBL408430; CTK8B9184; BDBM21283; MolPort-009-019-655; HMS3651A13; HMS3650F09; MFCD11045986; (R,S)-AM1241; (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole); ANW-62168; s1544; AKOS016004972; SB19545; CCG-208738; NCGC00165726-04; NCGC00165726-01; HY-18640; TC-150913; LS-192021; KB-206133; AX8233934; SW219858-1; CS-0011638; ST24033932; Z-3231
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22IN3O3
|
|||
| Canonical SMILES |
CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=C(C=CC(=C4)[N+](=O)[O-])I
|
|||
| InChI |
1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3
|
|||
| InChIKey |
ZUHIXXCLLBMBDW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 444912-48-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15133103, 22543339, 24891092, 29217481, 39980315, 49689355, 50075253, 57374267, 76284474, 103570243, 104253201, 123220371, 125333900, 125333901, 134223221, 134345535, 135727823, 136367459, 139525211, 140908975, 160829666, 162038067, 162108993, 163094098, 163394831, 163843884, 172855452, 175608141, 178100350, 185992953, 204434093, 228185242, 242810617, 245207288, 249853586, 249964872, 250212640, 252074940, 252437430, 252457872
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [2] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3316). | |||
| REF 2 | Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.